Johnson & Johnson

“Johnson & Johnson is a high-quality, defensively positioned healthcare compounder with a self-reinforcing R&D flywheel, CAR-T manufacturing moat, MedTech switching costs, and a fortress balance sheet generating ~$19B in annual free cash flow. The near-term Stelara biosimilar cliff is being absorbed by Darzalex and Carvykti, and MedTech organic growth is accelerating — but IRA drug pricing reform represents a structural, multi-year margin headwind that permanently reduces long-term pharma earnings power. Management is competent but not owner-operated, and the talc Texas Two-Step governance blemish cannot be dismissed. At 18x forward earnings and ~3.5% FCF yield, J&J is priced for market-rate returns of 6-8% annually — a good business at a fair price, not a great business at a cheap price. The right action is to track for a better entry around sub-15x forward earnings (~$190 or lower), at which point the risk/reward tilts decisively in the investor's favor.”